Skip to Main Content

++

This chapter deals with a number of deleterious adverse effects of treatments and environmental agents on the heart. Toxic effects can occur acutely and require emergent intervention or can be chronic and not be manifest until days or years after exposure.

++

Chemotherapeutic Agents

++

Chemotherapeutic agents can result in acute or chronic cardiovascular toxicity. The heart, composed of nonproliferating myocytes, was traditionally thought to be protected from the effects of drugs on rapidly dividing cells. A number of these agents are now recognized to cause cardiovascular complications including cardiomyopathy, myocarditis, pericarditis, myocardial ischemia, arrhythmias, and peripheral hypotension or vasospasm.1

++

Cardiovascular alterations in the patient receiving chemotherapy can be the result of a specific drug or combination of drugs or be related to tumor-associated factors such as hypercoagulability or release of myocardial depressant factors. Correlating a specific therapy with a particular adverse event can be difficult; however, knowledge of adverse effects of each agent should be considered when prescribing therapy.1-3

++

Anthracyclines

++

The anthracycline antineoplastics—doxorubicin, daunorubicin, idarubicin, and epirubicin—are the leading cause of chemotherapy-related heart disease. These agents can cause cardiac problems during therapy, weeks after completion of therapy, or, unexpectedly, years later.4 During acute therapy, electrocardiogram (ECG) changes occur in approximately 30% of patients and usually regress within weeks. Findings include ST-T wave changes, decreased QRS voltage, prolongation of the QT interval, and atrial and ventricular ectopy. Sustained atrial or ventricular arrhythmias are rare. The occurrence of early ECG abnormalities does not predict cardiomyopathy and is not an indication to discontinue therapy.1 The development of persistent sinus tachycardia in an otherwise stable oncology patient (although nonspecific), however, can raise the suspicion of ventricular dysfunction and impending congestive heart failure. Congestive heart failure is related to the cumulative dose of the anthracycline administered. The incidences of heart failure at specific doses of doxorubicin include 0.4% at 400 mg/m2 of body surface area, 7% at 550 mg/m2, and 18% at 700 mg/m2 (Fig. 94–1).5 Traditionally, the cardiac-limiting dose has been described as 550 mg/m2 because of the acute increase in heart failure seen above this dose. There is great individual variability, however, with reports of heart failure occurring with doses <100 mg/m2 and, conversely, with some patients tolerating >1000 mg/m2 without cardiac compromise.5,6 Risk factors for anthracycline-induced cardiomyopathy are debated but include prior chest radiation, young age (0-12 years of age), age >70 years, and preexisting heart disease.5-7 Young females can be at particularly increased risk for late cardiac dysfunction.7 Rapid infusion schedules associated with higher peak drug concentration appear to result in greater cardiotoxicity. Combination therapy with cyclophosphamide is an additional risk factor,1 with cardiotoxicity noted at doses of 300 mg/m2. The pathogenesis of anthracycline-induced cardiotoxicity is not known. Theories generally implicate free radical damage.8,9 The average time to clinical development of ...

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Subscription Options

AccessCardiology Full Site: One-Year Subscription

Connect to the full suite of AccessCardiology content and resources including textbooks such as Hurst's the Heart and Cardiology Clinical Questions, a unique library of multimedia, including heart imaging, an integrated drug database, and more.

$595 USD
Buy Now

Pay Per View: Timed Access to all of AccessCardiology

24 Hour Subscription $34.95

Buy Now

48 Hour Subscription $54.95

Buy Now

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.